A Clinical trial of compound drugs for patients with type2 diabetes - Comparative analysis of the characteristics of postprandial hyperglycemia improving drugs for postprandial metabolic disorder.
Not Applicable
- Conditions
- type2 diabetes
- Registration Number
- JPRN-UMIN000006199
- Lead Sponsor
- Advanced Clinical Research Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients having been treated by sulfonylureas within 3 months. 2) Patients treated by hyperlipidemia of fibrates. 3) Patients with a BMI of 40 or more. 4) Patients falling under the [contraindication] in attached files of the experimental drugs. 5) Patients falling under the [Special caution needed] in attached files of the experimental drugs and whom have high disability, and whom principal investigator concludes to be unsuitable for the test. 6) Patients whom principal investigator concludes to be unsuitable for the test, in other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy endpoints: Measure the summary statistics of the measurement value and the changing value of the parameter (glucose, insulin, triglycerides, RLP-C, free fatty acids) after a meal tolerance test. Measure the summary statistics of Emax, tmax and AUEC0-180. Safety endpoints: The incidence of adverse events and side effect. For laboratory evidence, summary statistics are calculated.
- Secondary Outcome Measures
Name Time Method